Bronchial Thermoplasty benefits for Uncontrolled Asthma sust
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Bronchial thermoplasty is an endoscopic treatment for uncontrolled asthma. The benefits of bronchial thermoplasty in patients with uncontrolled asthma are sustained over at least 10 years, according to results of the BT10+ study.

The BT10+ study aimed to investigate the efficacy and safety of bronchial thermoplasty after 10 or more years of follow-up. The study was published by The Lancet Respiratory Medicine.

BT10+ was an international, multicentre, follow-up study of participants who were previously enrolled in the AIR, RISA, and AIR2 trials and who had 10 or more years of follow-up since bronchial thermoplasty treatment. The primary effective endpoint was the durability of the thermoplasty treatment effect. The primary safety endpoint was the absence of clinically significant post-treatment respiratory image changes after bronchial thermoplasty, defined as bronchiectasis or bronchial stenosis.

The BT10+ study enrolled 192 of the 429 participants. The BT10+ participants comprised 136 who received bronchial thermoplasty, and 56 sham or control participants. 18 sham or control participants received bronchial thermoplasty after the previous trials concluded.

--Participants treated with bronchial thermoplasty had similar proportions of severe exacerbations at the BT10+ visit compared with 1 year and 5 years after treatment.

--Quality of life measurements and spirometry were similar between year 1, year 5, and the BT10+ visit.

--At the BT10+ study visit, pulmonary high-resolution CT scans from AIR2 participants treated with bronchial thermoplasty showed that 13 of 97 participants had bronchiectasis.

--When compared with baseline high-resolution CT scans, six of 89 participants treated with bronchial thermoplasty who did not have bronchiectasis at baseline had developed bronchiectasis after treatment.

--Participants treated with bronchial thermoplasty after the original study and participants in the sham or control group also had reductions in severe exacerbations at the BT10+ visit compared with baseline.

Conclusively, the efficacy of bronchial thermoplasty is sustained for 10 years or more, with an acceptable safety profile. Therefore, bronchial thermoplasty is a long-acting therapeutic option for patients with asthma that remains uncontrolled despite optimized medical treatment.

Source: https://doi.org/10.1016/S2213-2600(20)30408
1 share
Like
Comment
Share